Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset.
The post Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building appeared first on MedCity News.
